Drug Trial Radar · NCT05118763
Intranasal INNA-051 for Prevention of COVID-19 in Adults
Last checked: Nov 20, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 1, 2022
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- ENA Respiratory Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection. This study will evaluate 2 active dose levels of INNA-051 and placebo.
Conditions
- COVID-19 Pandemic
Interventions
INNA-051Drug
Liquid for intranasal administration
PlaceboOther
Liquid for intranasal administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the ability of INNA-051 to reduce the incidence of symptomatic RT-PCR confirmed SARS-CoV-2 infectionTime frame: To Day 14
- Evaluate the safety and tolerability of INNA 051.Time frame: To Day 42
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.